Abiopharma

🔍 Renninger Robert (Executive)

Company: Athira Pharma, Inc. (ATHA)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 1,000 shares of Common Stock at $2.31 per share (Direct)
  Date: 2025-11-18 | Code: A | equity_swap_involved: 0 | shares_owned_after: 11,918.00 | transaction_form_type: 5 | Footnotes: F1, F3, F4
• Acquired 1,236 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 13,154.00 | transaction_form_type: 4
• Sold 297 shares of Common Stock at $6.88 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,857.00 | transaction_form_type: 4 | Footnotes: F5, F6
• Sold 1,236 shares of Restricted Stock Units (Derivative)
  Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F7, F8, F9, F9

Footnotes:

• F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 19, 2025 through November 18, 2025. This transaction is also exempt under Rule 16b-3(c).
• F2: The reported number of shares in this Form 4 has been adjusted to reflect the impact of the Issuer's 10-for-1 reverse stock split completed on September 17, 2025 (the "Reverse Stock Split").
• F3: The Purchase Period ended November 18, 2025 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 19, 2025.
• F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2025.
• F5: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025.
• F6: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F7: RSUs convert into common stock on a one-for-one basis.
• F8: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.
• F9: On October 1, 2024, the reporting person was granted 3,707 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.